PaxMedica has Its Autism Spectrum Disorder Phase 2 Study Results Published in Peer-reviewed Journal

DENVER, Colo., Nov 7, 2023 ( PaxMedica Inc (NASDAQ: PXMD) stated, this morning, that the Annals of General Psychiatry published its research, led by Chief Medical Officer Dr. David Hough, results exploring the potential of low-dose suramin intravenous infusions as an ASD treatment, from a comprehensive, 14-week randomized, double-blind, placebo-controlled study that enrolled 52 boys aged 4-15 years with moderate to severe ASD.

PaxMedica is trading at $5.87, up $2.82 (+92.46%) on 5.55M premarket shares.

Its 52-week range is $0.2701 to $2.75. It set a new 52-week low last week and has popped multiple times in the past couple of months.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist